RPGL On Other Exchanges
Natl India

rpg life sciences ltd (RPGL) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RPG LIFE SCIENCES LTD (RPGL)

Related News

No related news articles were found.

rpg life sciences ltd (RPGL) Related Businessweek News

No Related Businessweek News Found

rpg life sciences ltd (RPGL) Details

RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic dosage forms, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company operates through Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients segments. It offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic/anti-depressant, anti-thrombotic, anti-anginal, anti-helmentic, anti-convulsant, anti-spasmodic, and anti-cancer. The company also provides generics primarily in the area of immunosuppressant therapy; and finished dosage formulations for various therapies, such as gastro-intestinal, pain management, cardio-vascular, and nephrology primarily under the Lomotil, Lomofen, Naprosyn, Azoran, Aldactone, and Serenace brands. In addition, it offers cosmetics, including evactive lubricating gel. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was founded in 1968 and is based in Mumbai, India.

Founded in 1968

rpg life sciences ltd (RPGL) Top Compensated Officers

MD & Additional Director
Total Annual Compensation: 375.0K
Compensation as of Fiscal Year 2018.
rpg life sciences ltd
Rpg Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019

RPG Life Sciences Limited announced earnings results for the fourth quarter ended March 31, 2019. For the fourth quarter, the company announced total revenue was INR 692.200 million compared to INR 837.800 million a year ago. Net income was INR 15.400 million compared to INR 12.500 million a year ago. Basic earnings per share was INR 0.93 compared to INR 0.76 a year ago. For the full year, total revenue was INR 3,309.600 million compared to INR 3,481.200 million a year ago. Net income was INR 108.100 million compared to INR 134.500 million a year ago. Basic earnings per share was INR 6.54 compared to INR 8.13 a year ago.

RPG Life Sciences Limited Recommends Dividend for the Financial Year Ended March 31, 2019

RPG Life Sciences Limited informed that the Board of Directors of the company has at its meeting held on April 29, 2019, approved the recommended an equity dividend of INR 2.40 per share of INR 8.00 each (30%) for the financial year ended March 31, 2019, which will be paid to the shareholders within 30 days of declaration of the same at the upcoming Annual General Meeting.

RPG Life Sciences Limited to Report Q4, 2019 Results on Apr 29, 2019

RPG Life Sciences Limited announced that they will report Q4, 2019 results on Apr 29, 2019


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

RPGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation RPGL Industry Range
Price/Earnings 38.7x
Price/Sales 1.3x
Price/Book 2.6x
Price/Cash Flow 16.0x
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact RPG LIFE SCIENCES LTD, please visit www.rpglifesciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.